South Delhi Pharma, New Delhi, India
ANDEXXA ® (coagulation factor Xa (recombinant), inactivated-zhzo)
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
ANDEXXA is a prescription medicine. ANDEXXA is used to treat uncontrolled bleeding.
INDICATIONS AND USAGE
ANDEXXA, coagulation factor Xa (recombinant), inactivated-zhzo is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is
needed due to life-threatening or uncontrolled bleeding.
DOSAGE FORMS & STRENGTHS
ANDEXXA is available as a lyophilized powder in single-use vials of 200 mg or 100 mg of coagulation factor Xa (recombinant), inactivated-zhzo
Manufactured By: Portola Pharmaceuticals, Inc.
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “ANDEXXA ® (coagulation factor Xa (recombinant), inactivated-zhzo)” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Factor X is part of fresh frozen plasma and the prothrombinase complex. There are two commercially available Factor X concentrates: "Factor X P Behring" manufactured by CSL Behring,[8] and high purity Factor X Coagadex produced by Bio Products Laboratory and approved for use in the United States by the FDA in October 2015, and in the EU in March 2016, after earlier acceptance by CHMP and COMP.
